epiPancancer

With epiPancancer, detect up to 33 types of cancer early through our breakthrough blood test, leveraging DNA methylation patterns for unmatched precision.

Current biomarkers lack sensitivity and specificity to detect cancer early. Available biomarkers and diagnostic methods are invasive and cannot be used for follow-up of a healthy population. Our scientists investigate DNA methylation results from normal tissues, blood, and cancer from thousands of people and used proprietary methods to discover unique methylation profiles that are categorically different between each tissue type. Our new Binary Categorical Differentiation (BCD) next-generation sequencing method identifies stark differences between cancer cells and normal cells.